Tejnaksh Health. (539428)

Score breakdown: P/E: 1/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Book value of ₹12.09 per share provides some tangible asset support for the current price.
• ROCE of 12.71% is higher than ROE, suggesting the business generates some operating return on capital employed.
• Healthcare services in India have long-term structural demand tailwinds, offering a potential recovery backdrop.
• Price of ₹23.46 is at the upper end of the 52-week range, indicating some market interest or momentum.

Concerns

• Sales growth declined 17.87% and profit growth fell 50.82%, showing a clearly shrinking business.
• Latest quarter net profit is ₹0 Cr on sales of ₹3 Cr, meaning near break-even or marginal operations.
• Piotroski F-Score of 3/9 signals weak financial health and operational deterioration.
• P/E of 20.26 with no dividend and no earnings growth offers no margin of safety for a value investor.

AI Analysis

At first glance, Tejnaksh Health looks like the kind of business I would walk past. Market price is ₹23.46 with a market cap of just ₹49 crore. The company earns a return on equity of only 6.81% — far below what an owner should demand from a healthcare service provider. Return on capital employed is better at 12.71%, but that does not compensate for the deterioration. Sales have fallen 17.87% and profits have collapsed by 50.82%. The latest quarter tells the story: ₹3 crore of sales produced essentially zero net profit. Piotroski F-score of 3 out of 9 is a red flag; it suggests fragile financial health. There is no dividend to reward shareholders while we wait. A P/E of 20.26 for a business with shrinking earnings and a P/B of 1.94 against book value of ₹12.09 offers no margin of safety. I cannot call this a wonderful business at a fair price; it is a mediocre business at an optimistic price. The price sits at the top of its 52-week range, but price momentum is not the same as value. In Graham's words, the market is a voting machine in the short term. This stock is being voted up on hope, not arithmetic. Could Tejnaksh Health turn around? Maybe, but as investors we do not rely on maybe. I need evidence of stabilised sales, improving margins, and a management that does something with the cash it earns. Until then, this is a pass.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer